10月20日 - ** 药物开发商Neuphoria Therapeutics NEUP.O股价在延时交易中下跌72%，至4.30美元
** 该公司称，其治疗社交焦虑症的实验性药物在一项后期试验中未能 (link)，因此NEUP停止了该项目的开发。
** 该公司正在社交焦虑症患者中测试 BNC210 药物，但该药物并未达到其主要目标，即减少公众演讲挑战中的痛苦。
** 截至 6 月 30 日，公司拥有 1,420 万美元现金，预计现金将持续到 2027 年第二季度
** 公司计划考虑开发用于治疗创伤后应激障碍的 BNC210
** 股价今年以来上涨了 349
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.